Matches in Wikidata for { <http://www.wikidata.org/entity/Q37344039> ?p ?o ?g. }
- Q37344039 description "2016 թվականի հոկտեմբերի 12-ին հրատարակված գիտական հոդված" @default.
- Q37344039 description "article científic" @default.
- Q37344039 description "article scientifique" @default.
- Q37344039 description "articolo scientifico" @default.
- Q37344039 description "artigo científico" @default.
- Q37344039 description "artículu científicu espublizáu en 2016" @default.
- Q37344039 description "bilimsel makale" @default.
- Q37344039 description "scientific article published on 12 October 2016" @default.
- Q37344039 description "vedecký článok" @default.
- Q37344039 description "vetenskaplig artikel" @default.
- Q37344039 description "videnskabelig artikel" @default.
- Q37344039 description "vědecký článek" @default.
- Q37344039 description "wetenschappelijk artikel" @default.
- Q37344039 description "wissenschaftlicher Artikel" @default.
- Q37344039 description "наукова стаття, опублікована в жовтні 2016" @default.
- Q37344039 description "научни чланак" @default.
- Q37344039 description "مقالة علمية نشرت في 12 أكتوبر 2016" @default.
- Q37344039 name "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 name "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 name "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 type Item @default.
- Q37344039 label "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 label "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 label "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 prefLabel "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 prefLabel "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 prefLabel "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 P1433 Q37344039-3F460AF5-670C-4FC9-87E6-EB9B08DC6FEE @default.
- Q37344039 P1476 Q37344039-165DEBD2-3FB1-48FB-9478-8620D7EA8471 @default.
- Q37344039 P2093 Q37344039-418EB922-98CF-4338-B224-A323357EBAB9 @default.
- Q37344039 P2093 Q37344039-4EAEC14B-823C-412D-9B8E-28515B81E130 @default.
- Q37344039 P2093 Q37344039-77742902-AF79-4C1D-9ED1-864A204CE5BF @default.
- Q37344039 P2093 Q37344039-8576303D-3BC1-4AE4-8B18-6119F3E469FF @default.
- Q37344039 P2093 Q37344039-CD15782C-18DB-4918-9AB3-7AF738952C03 @default.
- Q37344039 P2093 Q37344039-D284419C-EAF4-4857-835D-7C5D8D56F857 @default.
- Q37344039 P275 Q37344039-91ddf62a-add9-45e0-857c-b44e6ae405f8 @default.
- Q37344039 P2860 Q37344039-0B116FF3-8082-403B-BDB0-BA1A321F301C @default.
- Q37344039 P2860 Q37344039-16277FAC-F72D-4681-8DB6-5F36F8B6E05F @default.
- Q37344039 P2860 Q37344039-2242AF33-9F43-48A8-A778-BCB058C5399E @default.
- Q37344039 P2860 Q37344039-24C27C9E-BDC6-46C4-8B50-F58340EEEAE9 @default.
- Q37344039 P2860 Q37344039-2C0594AA-A64A-4DD4-B6CC-8F3D2FD1AE85 @default.
- Q37344039 P2860 Q37344039-3F991FF4-4222-4762-A3E1-504CC6909131 @default.
- Q37344039 P2860 Q37344039-41800318-3E72-46F4-A277-61A4E1944305 @default.
- Q37344039 P2860 Q37344039-4DBE16CB-40B8-4A82-911D-9E9C7F52F9C2 @default.
- Q37344039 P2860 Q37344039-55205FFC-776F-4930-9412-92AFF776B4B8 @default.
- Q37344039 P2860 Q37344039-5DB87865-A7B5-45E1-84D4-CE130EC44597 @default.
- Q37344039 P2860 Q37344039-70E1FF6A-2E27-48C3-8B81-C0DE42484FD7 @default.
- Q37344039 P2860 Q37344039-7A7ADB44-B0FD-4E15-BAEE-8BB211E3D932 @default.
- Q37344039 P2860 Q37344039-87E122B4-628E-40D4-B6AF-B807166334AE @default.
- Q37344039 P2860 Q37344039-A0408095-4820-490F-AE50-78EFEFE1D5B8 @default.
- Q37344039 P2860 Q37344039-A5177E57-C923-454B-A513-3C66C7D29617 @default.
- Q37344039 P2860 Q37344039-A69FBC40-AAE6-4EDB-843F-462042B9EDCA @default.
- Q37344039 P2860 Q37344039-A7721CEF-ADF3-4B15-8285-D2C805CA1F49 @default.
- Q37344039 P2860 Q37344039-A7923757-1865-4C40-BBAF-4A71F139E2A8 @default.
- Q37344039 P2860 Q37344039-AA79755A-1053-45EF-8209-B3C6C8B64DB7 @default.
- Q37344039 P2860 Q37344039-B41881D1-9719-4C34-9AC9-AC93FE0882A9 @default.
- Q37344039 P2860 Q37344039-B9A0B9E0-8C5D-439D-A810-592A3B3FF9F6 @default.
- Q37344039 P2860 Q37344039-BAD64731-00E2-4A58-9EC2-4528E6EAE93E @default.
- Q37344039 P2860 Q37344039-BB2BCE8A-13C7-4353-B961-30F89558173B @default.
- Q37344039 P2860 Q37344039-BBCE327D-BD79-4156-AB9E-D40153CC1183 @default.
- Q37344039 P2860 Q37344039-BCFCE404-1B35-4B03-9616-92E3364B9F45 @default.
- Q37344039 P2860 Q37344039-C1FCBD09-38A8-400A-B713-7700E4EBB4C4 @default.
- Q37344039 P2860 Q37344039-C243C525-6D91-40D7-B4E9-63ED6753E8D8 @default.
- Q37344039 P2860 Q37344039-CBF15CA4-9EFC-4505-8B11-03C6264EDCB0 @default.
- Q37344039 P2860 Q37344039-CD1C76CC-50AF-4214-80BF-C921A478E14E @default.
- Q37344039 P2860 Q37344039-D9036412-AC1B-4E95-B5BD-9EB0ACDF6AD4 @default.
- Q37344039 P2860 Q37344039-D9316913-BDB8-4B5A-83CE-B5991548F692 @default.
- Q37344039 P2860 Q37344039-EE8A6025-0E92-4B94-84C2-6FBA2C8E0C5D @default.
- Q37344039 P2860 Q37344039-F006BC2A-9260-4312-87C6-FB10AC284B30 @default.
- Q37344039 P2860 Q37344039-F1326BEB-E9FC-45A6-9764-36A258D3AB95 @default.
- Q37344039 P2860 Q37344039-F4378E0F-F5D0-489A-83E9-6A4CE3DFD3CA @default.
- Q37344039 P304 Q37344039-ADC10247-A219-42E8-8FF0-BE585F9C4BA6 @default.
- Q37344039 P31 Q37344039-16218DDE-1C46-4BD2-90DA-2B5BC44D9DD8 @default.
- Q37344039 P356 Q37344039-8FBA7A36-376F-4D82-A9CE-A43D31D40C23 @default.
- Q37344039 P407 Q37344039-B541368D-479E-4D57-97C0-60063BE5A52C @default.
- Q37344039 P478 Q37344039-BA93948D-CB9A-4961-8305-86D5B9091662 @default.
- Q37344039 P50 Q37344039-2C267D99-9F8D-414E-95D8-636E980CB62C @default.
- Q37344039 P50 Q37344039-706B1F16-5DF9-4690-8D2C-538FE9C31C58 @default.
- Q37344039 P577 Q37344039-B419C2DA-2AD4-4D8F-A487-1FDFDC87AAAF @default.
- Q37344039 P6216 Q37344039-e93e3ff5-9a66-4589-a601-aa8bcc37ae87 @default.
- Q37344039 P698 Q37344039-8E9E1B51-DBDF-46B4-BE71-5D9636B30D14 @default.
- Q37344039 P921 Q37344039-86075E0C-5DAA-4750-8BAB-DE595AB87799 @default.
- Q37344039 P921 Q37344039-AABA19FF-6EFE-4863-AB6B-64AD46854ADD @default.
- Q37344039 P932 Q37344039-0E1C513B-56A7-4D4C-AAE8-C0424813B150 @default.
- Q37344039 P356 CEOR.S107831 @default.
- Q37344039 P698 27785081 @default.
- Q37344039 P1433 Q5133862 @default.
- Q37344039 P1476 "Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece" @default.
- Q37344039 P2093 "Aikaterini Bilitou" @default.
- Q37344039 P2093 "Apostolos Karavidas" @default.
- Q37344039 P2093 "Dawn Lee" @default.
- Q37344039 P2093 "Georgia Sykara" @default.
- Q37344039 P2093 "John Kyriopoulos" @default.
- Q37344039 P2093 "John Parissis" @default.
- Q37344039 P275 Q18810331 @default.
- Q37344039 P2860 Q27015133 @default.
- Q37344039 P2860 Q30358659 @default.
- Q37344039 P2860 Q34035122 @default.
- Q37344039 P2860 Q34130575 @default.
- Q37344039 P2860 Q34187441 @default.